|Day Low/High||22.69 / 23.97|
|52 Wk Low/High||4.35 / 20.65|
- Data presented at The American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting -
Ark Invest has developed a series of specialized exchange-traded funds that own shares in companies involved in 'disruptive innovation.'
In recent trading, shares of Invitae Corp have crossed above the average analyst 12-month target price of $22.96, changing hands for $22.97/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.
SAN FRANCISCO, March 14, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the Oppenheimer 29th Annual Healthcare...
Jim Cramer looks at Boeing, Dick's Sporting Goods and more -- and shows investors how to really understand the markets and stock-picking.
Jim Cramer weighs in on Charles Schwab, Invitae, Weibo, Alibaba, Charles River Labs, AeroVironment, Ormat Technologies.
SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the exercise in full of the underwriters' option to purchase an additional 1,350,000 shares of its common stock at the public offering price of $19.
SAN FRANCISCO, March 5, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $19.
SAN FRANCISCO, March 4, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $125.
--Stoke Therapeutics and Xenon Pharmaceuticals Join Founders BioMarin and Invitae to Offer a No-Cost Epilepsy Gene Panel Testing Program for Children Up to 60 Months Who Have Had an Unprovoked Seizure--
When the indices aren't offering much opportunity money flows into individual speculative names.
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
SAN FRANCISCO, Feb. 13, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 8th Annual SVB Leerink Global Healthcare...
-- In Combination with Carrier Screening, NIPS Provides Affordable, Streamlined Access to Genetic Testing for Parents-to-Be --
-- Largest Dataset of Prostate Cancer Patients Shows 17% Have Increased Risk Based on Genetic Analysis --
SAN FRANCISCO, Jan. 29, 2019 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), the fastest growing clinical genetics company, today announced that it will report its fourth quarter and year-end 2018 financial results on Tuesday, February 19, 2019 and will...
Jim Cramer's plan for getting through the heart of earnings season next week.
Jim Cramer weighs in on Cronos, Fortinet, Dominion Energy and more.
Investors in Invitae Corp saw new options become available this week, for the February 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NVTA options chain for the new February 15th contracts and identified one put and one call contract of particular interest.
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
In trading on Friday, shares of Invitae Corp crossed below their 200 day moving average of $10.05, changing hands as low as $9.44 per share. Invitae Corp shares are currently trading down about 9.7% on the day.
SAN FRANCISCO, Dec. 20, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, today announced that Sean George, co-founder and chief executive officer of Invitae, will present at the 37th Annual J.
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
-- Data shows current guidelines exclude many patients with medically relevant genetic changes --
-- Research highlights frequency of medically actionable variants among secondary findings --
-- Part of Invitae's network of partnerships, program supports early diagnosis to help patients and their clinicians make more informed decisions about their health --
Jim Cramer takes a closer look at PayPal, Senseonomics, Idexx Laboratories, Sonos, Denbury Resources, Apptio, Invitae, Wayfair, JD.com, and McDonald's.
Jim Cramer says Wall Street isn't very worried about tariffs. He highlights the stocks with China exposure and looks at the potential impact.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.